The global neuropathy pain treatment market is projected to grow to USD 6,948.98 million by 2021, at a
CAGR of close to 6% over the forecast period, according to Technavio’s latest
report.
Technavio’s research study segments the global neuropathy pain
treatment market into the following regions:
·
Americas
·
EMEA
·
APAC
Neuropathy pain treatment market in the Americas
Currently, there is a growing focus on developing drugs for
diseases such as postherpetic neuralgia, which will propel the market growth
over the forecast period. Vendors are also seeking to increase market
penetration by adopting inorganic growth strategies to expand their expertise.
Technavio’s sample reports are free of charge and contain
multiple sections of the report including the market size and forecast,
drivers, challenges, trends, and more.
Neuropathy pain treatment market in EMEA
The market for neuropathy
treatment in EMEA is expected to be worth USD 2,167.39 million by
2021. The growing awareness and well-established healthcare infrastructure in
Europe have led to the higher demand for neuropathic pain drugs, mainly for
diabetic neuropathy. Countries such as the UK, Italy, Spain, Germany, and
France are witnessing an increased uptake of drugs for the treatment of
diabetic neuropathy, which is expected to fuel the market growth in EMEA. The
increased adoption of low-cost generics in the Middle East and Africa will
affect the market dynamics in EMEA.
Neuropathy pain treatment market in APAC
Patent expiries of key branded therapies such as Eli Lilly’s
Cymbalta are creating new opportunities in untapped markets for generics. In
addition, the market looks promising in this region due to an increasing number
of the geriatric demographic and the large population pool, especially in India
and China, are likely to drive the market growth.
The top vendors in the global neuropathy pain treatment market
highlighted in the report are:
·
Depomed
·
Eli Lilly
·
Endo International
·
Pfizer
No comments:
Post a Comment